Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (247) 247
female (134) 134
male (127) 127
aged (120) 120
middle aged (111) 111
anticoagulants - therapeutic use (94) 94
venous thromboembolism (92) 92
anticoagulants (91) 91
index medicus (86) 86
prevention (85) 85
treatment outcome (76) 76
thromboembolism (75) 75
hematology (71) 71
risk factors (71) 71
deep-vein thrombosis (70) 70
medicine, general & internal (67) 67
anticoagulants - administration & dosage (64) 64
thromboembolism - prevention & control (64) 64
peripheral vascular disease (58) 58
drug therapy (57) 57
enoxaparin (57) 57
hemorrhage - chemically induced (57) 57
venous thrombosis - prevention & control (57) 57
adult (56) 56
cardiac & cardiovascular systems (56) 56
rivaroxaban (54) 54
anticoagulants - adverse effects (51) 51
warfarin (51) 51
double-blind method (50) 50
thrombosis (47) 47
heparin (45) 45
stroke (42) 42
surgery (42) 42
aged, 80 and over (39) 39
molecular-weight heparin (39) 39
venous thrombosis (39) 39
atrial fibrillation (37) 37
fibrinolytic agents - therapeutic use (37) 37
administration, oral (35) 35
enoxaparin - therapeutic use (34) 34
thromboprophylaxis (34) 34
heparin, low-molecular-weight - therapeutic use (33) 33
unfractionated heparin (30) 30
drug administration schedule (29) 29
polysaccharides - therapeutic use (29) 29
prospective studies (29) 29
pulmonary-embolism (29) 29
care and treatment (28) 28
clinical trials as topic (28) 28
management (28) 28
heparin - therapeutic use (27) 27
postoperative complications - prevention & control (26) 26
randomized controlled trials as topic (26) 26
thromboembolism - drug therapy (26) 26
prophylaxis (25) 25
time factors (25) 25
venous thromboembolism - prevention & control (25) 25
acute disease (24) 24
aspirin (24) 24
health aspects (24) 24
patients (24) 24
therapy (23) 23
venous thrombosis - drug therapy (23) 23
abridged index medicus (22) 22
analysis (22) 22
factor xa inhibitors (22) 22
fondaparinux (22) 22
risk (22) 22
thromboembolism - etiology (22) 22
bleeding (21) 21
dose-response relationship, drug (21) 21
fibrinolytic agents - adverse effects (21) 21
follow-up studies (21) 21
mortality (21) 21
pulmonary embolism - prevention & control (21) 21
safety (21) 21
clinical trials (20) 20
diagnosis (20) 20
dosage and administration (20) 20
enoxaparin - administration & dosage (20) 20
evaluation (20) 20
warfarin - therapeutic use (20) 20
fibrinolytic agents - administration & dosage (19) 19
pulmonary embolism (19) 19
anticoagulation (18) 18
clinical medicine (18) 18
health risk assessment (18) 18
heparin, low-molecular-weight - administration & dosage (18) 18
incidence (18) 18
unstable angina (18) 18
atrial fibrillation - drug therapy (17) 17
cardiology (17) 17
embolisms (17) 17
enoxaparin - adverse effects (17) 17
low-molecular-weight heparin (17) 17
antithrombotic therapy (16) 16
double-blind (16) 16
hemorrhage (16) 16
hospitalization (16) 16
international normalized ratio (16) 16
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: Pooled analysis of four studies
by Turpie, Alexander G. G and Lassen, Michael Rud and Eriksson, Bengt I and Gent, Michael and Berkowitz, Scott D and Misselwitz, Frank and Bandel, Tiemo J and Homering, Martin and Westermeier, Torsten and Kakkar, Ajay K
Thrombosis and Haemostasis, ISSN 0340-6245, 03/2011, Volume 105, Issue 3, pp. 444 - 453
Four phase III studies compared oral rivaroxaban with subcutaneous enoxaparin for the prevention of venous thromboembolism (VTE) after total hip or knee... 
Pooled analysis | Rivaroxaban | Venous thromboembolism | Double-Blind Method | Administration, Oral | Humans | Middle Aged | Morpholines - administration & dosage | Male | Treatment Outcome | Thiophenes - administration & dosage | Venous Thromboembolism - drug therapy | Arthroplasty, Replacement, Hip - methods | Clinical Trials, Phase III as Topic | Enoxaparin - administration & dosage | Adolescent | Arthroplasty, Replacement, Knee - methods | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: A randomized trial
by Hull, Russell D and Schellong, Sebastian M and Tapson, Victor F and Monreal, Manuel and Samama, Meyer-Michel and Nicol, Philippe and Vicaut, Eric and Turpie, Alexander G. G and Yusen, Roger D and EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study
Annals of Internal Medicine, ISSN 0003-4819, 07/2010, Volume 153, Issue 1, pp. 8 - 18
Extended-duration low-molecular-weight heparin has been shown to prevent venous thromboembolism (VTE) in high-risk surgical patients. To evaluate the efficacy... 
Acute Disease | Anticoagulants - administration & dosage | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Risk Factors | Male | Treatment Outcome | Hospitalization | Immobilization - adverse effects | Anticoagulants - adverse effects | Enoxaparin - adverse effects | Incidence | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Aged, 80 and over | Adult | Female | Aged | Hemorrhage - chemically induced | Venous Thromboembolism - epidemiology | Delayed-Action Preparations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Fondaparinux Sodium: A Viewpoint by Alexander G. G. Turpie
by Turpie A.G.G
Drugs, ISSN 0012-6667, 2002, Volume 62, Issue 11, pp. 1686 - 1687
New drug profiles | Fondaparinux sodium, general | Venous thrombosis, prevention | Factor Xa inhibitors, general | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry
by Kakkar, A.K and Mueller, I and Bassand, J.P and Fitzmaurice, D.A and Goldhaber, S.Z and Goto, S and Haas, S and Hacke, W and Lip, G.Y and Mantovani, L.G and Turpie, A.G.G and Eickels, M. van and Misselwitz, F and Rushton-Smith, S and Kayani, G and Wilkinson, P and Verheugt, F.W.A and et al and GARFIELD Registry Investigators and for the GARFIELD Registry Investigators
Plos One, ISSN 1932-6203, 2013, Volume 8, Issue 5, p. e63479
BACKGROUND: Limited data are available on the characteristics, clinical management, and outcomes of patients with atrial fibrillation at risk of stroke, from a... 
PREDICTING STROKE | ACC/AHA/ESC 2006 GUIDELINES | MANAGEMENT | TASK-FORCE | WARFARIN | PROGNOSIS | MULTIDISCIPLINARY SCIENCES | EURO HEART SURVEY | PREVALENCE | THROMBOEMBOLISM | SOCIETY | Prospective Studies | Atrial Fibrillation - drug therapy | Humans | Risk Factors | Atrial Fibrillation - complications | Molecular Sequence Data | Male | Stroke - drug therapy | Contraindications | Randomized Controlled Trials as Topic | Stroke - etiology | Vitamin K - antagonists & inhibitors | Fibrinolytic Agents - therapeutic use | Female | Registries | Aged | Atrial Fibrillation - diagnosis | Stroke (Disease) | Medical research | Care and treatment | Atrial fibrillation | Medicine, Experimental | Anticoagulants (Medicine) | Health aspects | Risk factors | Heart | Drugs | Therapy | Cardiac arrhythmia | Demography | Ethics | Demographics | Fibrillation | Cardiology | Age | Vitamin K | Hypertension | Anticoagulants | Stroke | Enrollments | Health risks | Patients | Thrombosis | Medicine | Hospitals | Adults | Diabetes | Clinical medicine | Risk management
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial
by Cohen, Alexander T and Davidson, Bruce L and Gallus, Alexander S and Lassen, Michael R and Prins, Martin H and Tomkowski, Witold and Turpie, Alexander G G and Egberts, Jan F M and Lensing, Anthonie W A and ARTEMIS Investigators
BMJ, ISSN 0959-8138, 02/2006, Volume 332, Issue 7537, pp. 325 - 327
Abstract Objective To determine the efficacy and safety of the anticoagulant fondaparinux in older acute medical inpatients at moderate to high risk of venous... 
Medical research | Lung diseases | Medical specialists | Placebos | Hospital admissions | Venous thrombosis | Research | Pulmonary embolisms | Bleeding | Phlebography | Diseases | ENOXAPARIN | SURGERY | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | FATAL PULMONARY-EMBOLISM | DEEP-VEIN THROMBOSIS | THROMBOPROPHYLAXIS | HEPARIN | Polysaccharides - therapeutic use | Acute Disease | Double-Blind Method | Follow-Up Studies | Humans | Middle Aged | Polysaccharides - adverse effects | Anticoagulants - therapeutic use | Male | Treatment Outcome | Hospitalization | Anticoagulants - adverse effects | Bed Rest - adverse effects | Disease-Free Survival | Thromboembolism - prevention & control | Female | Venous Thrombosis - prevention & control | Aged | Hemorrhage - chemically induced | Chronic Disease
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
by Douketis, James D and Spyropoulos, Alex C and Kaatz, Scott and Becker, Richard C and Caprini, Joseph A and Dunn, Andrew S and Garcia, David A and Jacobson, Alan and Jaffer, Amir K and Kong, David F and Schulman, Sam and Turpie, Alexander G.G and Hasselblad, Vic and Ortel, Thomas L and Bridge Investigators and BRIDGE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 9, pp. 823 - 833
In this trial, patients with atrial fibrillation who required warfarin interruption for an elective procedure were assigned to either bridging anticoagulation... 
VITAMIN-K-ANTAGONISTS | MEDICINE, GENERAL & INTERNAL | WARFARIN THERAPY | TERM ORAL ANTICOAGULANTS | MOLECULAR-WEIGHT HEPARIN | ANTITHROMBOTIC THERAPY | INVASIVE PROCEDURES | TEMPORARY INTERRUPTION | PERIPROCEDURAL ANTICOAGULATION | ELECTIVE SURGERY | CLINICAL-OUTCOMES | Anticoagulants - administration & dosage | Double-Blind Method | Atrial Fibrillation - drug therapy | Humans | Postoperative Complications - prevention & control | Heparin, Low-Molecular-Weight - adverse effects | Warfarin - adverse effects | Male | Anticoagulants - adverse effects | Warfarin - administration & dosage | Perioperative Period | Thromboembolism - prevention & control | Adult | Female | Hemorrhage - chemically induced | Heparin, Low-Molecular-Weight - administration & dosage | Elective Surgical Procedures | Prevention | Care and treatment | Warfarin | Usage | Atrial fibrillation | Clinical trials | Dosage and administration | Hemorrhage | Risk factors | Cardiac arrhythmia | Anticoagulants | Stroke | Transient ischemic attack | Body weight | Preventive medicine | Patients | Bleeding | Embolism | Fibrillation | Ischemia | Surgery | Heparin | Thromboembolism | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases
by Turpie, Alexander G.G
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 06/2007, Volume 27, Issue 6, pp. 1238 - 1247
Anticoagulants are recommended for the prevention and treatment of a wide variety of thromboembolic events. Although existing anticoagulants are effective,... 
Stroke | Anticoagulant | Atrial fibrillation | Venous thromboembolism | Factor Xa inhibitor | RIVAROXABAN BAY-59-7939 | BAY 59-7939 | PROTHROMBINASE COMPLEX | DEEP-VEIN THROMBOSIS | anticoagulant | stroke | atrial fibrillation | IN-VITRO | venous thromboembolism | MOLECULAR-WEIGHT HEPARIN | ANTITHROMBOTIC THERAPY | TOTAL HIP-REPLACEMENT | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | UNFRACTIONATED HEPARIN | Glycine - analogs & derivatives | Glycine - therapeutic use | Thiophenes - therapeutic use | Drugs, Investigational - pharmacology | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Administration, Oral | Humans | Drugs, Investigational - therapeutic use | Anticoagulants - therapeutic use | Treatment Outcome | Piperazines - therapeutic use | Factor Xa - metabolism | Rivaroxaban | Animals | Thromboembolism - blood | Blood Coagulation - drug effects | Thromboembolism - prevention & control | Anticoagulants - pharmacology | Drugs, Investigational - administration & dosage | Thromboembolism - drug therapy | Morpholines - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
by Lassen, Michael R and Ageno, Walter and Borris, Lars C and Lieberman, Jay R and Rosencher, Nadia and Bandel, Tiemo J and Misselwitz, Frank and Turpie, Alexander G.G and RECORD3 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 06/2008, Volume 358, Issue 26, pp. 2776 - 2786
This trial compared rivaroxaban with enoxaparin for thromboprophylaxis after total knee replacement. Rivaroxaban was superior to enoxaparin in the prevention... 
MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | BAY-59-7939 | VENOUS THROMBOEMBOLISM | DOSE-RESPONSE | BAY 59-7939 | PARALLEL-GROUP | DOUBLE-BLIND | PREVENTION | TOTAL HIP-REPLACEMENT | DEEP-VEIN THROMBOSIS | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Arthroplasty, Replacement, Knee | Female | Venous Thrombosis - prevention & control | Venous Thromboembolism - epidemiology | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Aged | Enoxaparin | Arthroplasty | Blood coagulation factors | Comparative analysis | Health aspects | Patient outcomes | Knee | Comparative studies | Clinical trials | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer
by Agnelli, Giancarlo and George, Daniel J and Kakkar, Ajay K and Fisher, William and Lassen, Michael R and Mismetti, Patrick and Mouret, Patrick and Chaudhari, Umesh and Lawson, Francesca and Turpie, Alexander G.G and SAVE-ONCO Investigators
The New England Journal of Medicine, ISSN 0028-4793, 02/2012, Volume 366, Issue 7, pp. 601 - 609
Patients with advanced cancer are at increased risk for venous thrombosis and thromboembolism related to both the effects of cancer and its treatment. In this... 
CONTROLLED CLINICAL-TRIAL | SURGERY | MEDICINE, GENERAL & INTERNAL | EVENTS | VENOUS THROMBOEMBOLISM | PROGNOSTIC-FACTORS | COMPETING RISK | THROMBOSIS | BEVACIZUMAB | MOLECULAR-WEIGHT HEPARIN | PREVENTION | Double-Blind Method | Hemorrhage - epidemiology | Humans | Risk Factors | Kaplan-Meier Estimate | Heparin, Low-Molecular-Weight - adverse effects | Antineoplastic Agents - therapeutic use | Heparin, Low-Molecular-Weight - therapeutic use | Incidence | Neoplasms - drug therapy | Venous Thromboembolism - etiology | Fibrinolytic Agents - adverse effects | Fibrinopeptide A - adverse effects | Neoplasms - complications | Venous Thromboembolism - prevention & control | Fibrinopeptide A - therapeutic use | Antineoplastic Agents - adverse effects | Fibrinolytic Agents - therapeutic use | Adult | Venous Thromboembolism - epidemiology | Drugs | Cancer patients | Care and treatment | Drug utilization | Anticoagulants (Medicine) | Dosage and administration | Product/Service Evaluations | Thromboembolism | Drug therapy | Health aspects | Methods | Thrombolytic therapy | Anticoagulants | Embolisms | Prophylaxis | Clinical trials | Metastasis | Thrombosis | Cancer therapies | Patients | Bleeding | Embolism | Metastases | Studies | Chemotherapy | Heparin | Solid tumors | Health risk assessment | Drug dosages | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation
by Camm, A John and Accetta, Gabriele and Ambrosio, Giuseppe and Atar, Dan and Bassand, Jean-Pierre and Berge, Eivind and Cools, Frank and Fitzmaurice, David A and Goldhaber, Samuel Z and Goto, Shinya and Haas, Sylvia and Kayani, Gloria and Koretsune, Yukihiro and Mantovani, Lorenzo G and Misselwitz, Frank and Oh, Seil and Turpie, Alexander G G and Verheugt, Freek W A and Kakkar, Ajay K and GARFIELD-AF Investigators
Heart, ISSN 1355-6037, 02/2017, Volume 103, Issue 4, pp. 307 - 314
ObjectiveWe studied evolving antithrombotic therapy patterns in patients with newly diagnosed non-valvular atrial fibrillation (AF) and ≥1 additional stroke... 
CARDIAC & CARDIOVASCULAR SYSTEMS | THERAPY | STROKE PREVENTION | RISK-FACTOR | WARFARIN | TRANSIENT ISCHEMIC ATTACK | GLOBAL ANTICOAGULANT REGISTRY | GUIDELINES | EURO HEART SURVEY | SUBGROUP ANALYSIS | THROMBOEMBOLISM | Prospective Studies | Age Factors | Humans | Middle Aged | Stroke - diagnosis | Male | Fibrinolytic Agents - adverse effects | Time Factors | Aged, 80 and over | Female | Registries | Stroke - epidemiology | Atrial Fibrillation - diagnosis | Stroke - prevention & control | Risk Assessment | Administration, Oral | Atrial Fibrillation - drug therapy | Comorbidity | Risk Factors | Treatment Outcome | Practice Patterns, Physicians' - trends | Guideline Adherence | Atrial Fibrillation - epidemiology | Sex Factors | Aged | Fibrinolytic Agents - administration & dosage | Practice Guidelines as Topic | Stroke (Disease) | Care and treatment | Usage | Atrial fibrillation | Diagnosis | Thrombolytic drugs | Patients | Health aspects | Risk factors | Arrhythmias and Sudden Death | 1506 | Stroke
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights